MPs and peers must act urgently to avert potential scandal from drug industry payments and connections to parliamentary interest groups, researchers have said.

A new study of pharmaceutical firms’ dealings with All Party Parliamentary Groups (APPGs) has flagged fresh concerns over transparency and “disjointed disclosure” mechanisms.

The report, Into the Web , by the privately owned Patient Experience Library and which was supported by funding from the Joseph Rowntree Reform Trust, was published alongside a new online tool to help the public identify and track links between APPGs and industry. 1 2

Experts said the findings strengthened the case for the UK to introduce new “sunshine legislation” that would legally require full disclosure of all recipients of industry payments, with d

See Full Page